Evaluation of COVID-19 infection in patients with Neuromyelitis optica spectrum disorder (NMOSD): A report from Iran

COVID-19 infection in NMO/SD patients: a French survey

“…In this systematic survey of 75 NMO/SD patients, 6.7% had a highly suspected or confirmed COVID-19, which is consistent with the estimated seroprevalence in Ilede-France [5]. This rate is slightly higher than the 3.8% prevalence reported in an Iranian study [6], while a large survey in China described a very low risk of COVID-19: 2 confirmed COVID-19 pneumonia out of 3060 NMO/SD patients [7]. Despite ongoing immunosuppressive therapy, no severe infection was encountered in our study.…”

COVID-19 and disease-modifying therapies in patients with demyelinating diseases of the central nervous system: A systematic review

“…Overall, the data of 2493 MS patients and 37 NMOSD patients were reported with COVID-19. ( Table 1 , 2 ) ( Sahraian et al, 2020 , Safavi et al, 2020 , Bowen et al, 2020 , Louapre et al, 2020 , Dalla Costa et al, 2020 , Parrotta et al, 2020 , Barzegar et al, 2020 , Ciampi et al, 2020 , Mantero et al, 2020 , Sahraian et al, 2020 , Nesbitt et al, 2020 , Chaudhry et al, 2020 , Castillo Álvarez et al, 2020 , Shalhoub, 2020 , Delbue et al, 2007 , Berger and Brandstadter, 2020 , Maillart et al, 2020 , Ciampi et al, 2020 , Mantero et al, 2020 , Crescenzo et al, 2020 , Mehta et al, 2019 , Maghzi et al, 2020 , Möhn et al, 2020 , Bollo et al, 2020 , Ciardi et al, 2020 , Valencia-Sanchez and Wingerchuk, 2020 , Foerch et al, 2020 , Barzegar et al, 2020 , Chiarini et al, 2020 , Gomez-Mayordomo et al, 2020 , Mallucci et al, 2020 , Giovannoni et al, 2020 , Borriello and Ianniello, 2020 , Louapre et al, 2020 , Aguirre et al, 2020 , Rimmer et al, 2020 , Luna et al, 2019 , Carandini et al, 2020 , Matías-Guiu et al, 2020 , Guevara et al, 2020 , Fernández-Díaz et al, 2020 , Amor et al, 2020 , Fiorella and Lorna, 2020 , Dersch et al, 2020 , De Angelis et al, 2020 , Celius, 2020 , Jack et al, 2020 , Suwanwongse and Shabarek, 2020 , Ghajarzadeh et al, 2020 , Montero-Escribano et al, 2020 , Novi et al, 2020 , …”

“…Patients with chronic diseases and those receiving immunosuppressive therapies have an increased risk of infection and severe complications. ( Sahraian et al, 2020 ) Especially In the latter group of patients, the pandemic affects many aspects of their disease management, from therapeutic strategies to scheduling routine clinical follow-up and rehabilitation plans. Patients with demyelinating disorders of the central nervous system (CNS) such as Multiple Sclerosis (MS) or Neuromyelitis Optica Spectrum Disorder (NMOSD) deserve particular consideration due to their need for immunosuppressive or immunomodulatory therapies and regular monitoring of disease activity and response to treatment.…”

“…Patients with demyelinating disorders of the central nervous system (CNS) such as Multiple Sclerosis (MS) or Neuromyelitis Optica Spectrum Disorder (NMOSD) deserve particular consideration due to their need for immunosuppressive or immunomodulatory therapies and regular monitoring of disease activity and response to treatment. ( Sahraian et al, 2020 ) In this study, we review the latest evidence on 1) the effect of different disease-modifying therapies (DMT) on the risk of contracting SARS-CoV-2 infection and severe COVID-19 complications; 2) the effect of these therapies on the ability to develop immune responses to vaccines, and 3) the psychological impact of COVID-19 pandemic on patients with chronic demyelinating diseases.…”

COVID-19 in MS and NMOSD: A multicentric online national survey in Chile

“…Multivariate analyses determined that EDSS, age and obesity were independent risk factors for hospitalization or more severe COVID-19, while no association between disease-modifying therapy exposure and COVID-19 severity was observed ( Louapre et al., 2020 ). In NMOSD fewer articles have been published, also suggesting a similar rate of infection compared to the general population ( Sahraian et al., 2020 ).…”